PQQ

PQQ (pyrroloquinoline quinone) emerged from microbiology research as a bacterial cofactor before anyone considered it a human supplement. Its appeal rests on a compelling mechanistic triad: stimulation of mitochondrial biogenesis via PGC-1α activation, Nrf2-mediated upregulation of endogenous antioxidant enzymes, and direct protection of neurons from glutamate-induced oxidative toxicity. These are real cellular effects documented in vitro and in animal models. The critical question is whether they translate to meaningful human outcomes.

The human evidence base is thin but growing. Harris and colleagues (2013, Journal of Nutritional Biochemistry, PMID 23664328) conducted a small trial in 10 healthy adults, testing 0, 10, and 20 mg PQQ daily over three separate 72-hour periods. At the 20 mg dose, plasma PQQ reached detectable levels and urinary metabolites indicated robust absorption. Inflammatory markers including C-reactive protein and IL-6 showed trends toward reduction, and subjects reported improved sleep quality and vigor on subjective questionnaires. This is a pilot study with all the limitations that implies—small sample, short duration, no placebo control in the subjective measures—but it established human bioavailability and suggested biological activity.

The skin and cognitive data offer more structured trial evidence. Nakano and colleagues (2015, Journal of Nutritional Science and Vitaminology, PMID 26226961) administered 20 mg PQQ daily for 8 weeks to healthy women with dry skin and found significant inhibition of transepidermal water loss (TEWL) on the forearm, indicating improved skin barrier function. More recently, Tamakoshi and colleagues (2023, Food & Function, PMID 36807425) conducted a 12-week double-blind placebo-controlled trial in 41 adults aged 20–65, testing 20 mg PQQ daily. The results showed significant improvements in composite memory and verbal memory compared to placebo, with age-stratified analysis revealing that younger adults (20–40) improved in cognitive flexibility and processing speed at 8 weeks, while older adults (41–65) showed complex and verbal memory gains at 12 weeks. This is the strongest human cognitive trial for PQQ to date, though still modest in size.

The mitochondrial biogenesis claim requires careful parsing. In mouse and cell culture studies, PQQ robustly increases mitochondrial number and function. Human evidence for this specific endpoint is indirect. No human trial has directly measured mitochondrial DNA copy number or respiratory chain complex activity after PQQ supplementation. The biogenesis narrative is extrapolated from animal data and from modest improvements in subjective energy and metabolic biomarkers. This does not mean the effect is absent—only that it remains mechanistically plausible but clinically unproven in humans. The “vitamin” debate is worth addressing: some researchers have argued PQQ should be classified as a novel vitamin, but no human deficiency syndrome has been identified, and the body appears to function adequately without dietary PQQ.